The Medicines Company To Present New Data From TANGO II Study Of VABOMERE (Meropenem And Vaborbactam) At IDWeek 2017
Published: Oct 05, 2017
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that new data from its TANGO II study of VABOMERE (meropenem and vaborbactam) will be presented this week at IDWeek 2017 in San Diego.
In the TANGO II study, VABOMERE was associated with a higher clinical cure versus “best available therapy” (BAT) in patients with a baseline organism that was carbapenem-resistant Enterobacteriaceae (mCRE-MITT population) at both end-of-therapy (EOT) (VABOMERE 64.3% vs. BAT 33.3%; p=0.04) and test-of-cure (TOC) (VABOMERE 57.1% vs. BAT 26.7%; p=0.04). In immunocompromised patients, VABOMERE was also associated with a higher clinical cure versus BAT at EOT (VABOMERE 60% vs. BAT 12.5%; p<0.01), as well as lower mortality.